Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

All of this has helped Lilly's revenue climb in the double digits in recent quarters and the stock price to take off. The shares have advanced more than 200% over the past three years. Now the ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Zeroing in on Eli Lilly, the company is already well established ... On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think ...